# Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

> **NCT04036435** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 1466 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** BMS-986165
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04036435
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-12
- **Primary completion:** 2026-07-25
- **Final completion:** 2026-07-26
- **Target enrollment:** 1466 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04036435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04036435, "Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04036435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*